NVF M&A Exits: Our Successes
Since its foundation in 1996, the Novartis Venture Fund has developed exit strategies that have helped guide over 30 of its portfolio companies to successfully complete transformational M&A transactions with a diverse group of large international pharmaceutical companies.
Explore our M&A successes
Ablation Frontiers
Ablation Frontiers was acquired by Medtronic, Inc. in 2009.
Adenosine Therapeutics
Adenosine Therapeutics was acquired by Clinical Data, Inc. in 2008.
Alios BioPharma
Alios BioPharma was acquired by Johnson & Johnson in 2014.
Arctos Medical
Arctos Medical was acquired by Novartis in 2021.
Avila Therapeutics
Avila Therapeutics was acquired by Celgene Corp. in 2012.
Cavion
Cavion was acquired by Jazz Pharmaceuticals in 2019.
Cequent Pharmaceuticals
Cequent Pharmaceuticals was acquired by Marina Biotech in 2010.
Covagen
Covagen AG was acquired by Johnson & Johnson in 2014.
Discovery Technologies
Discovery Technologies was acquired by Discovery Partners in 1999.
Enterprise TMEM16A
Enterprise Therapeutics' novel TMEM16A potentiator portfolio was acquired by Roche in 2020.
EraGen Biosciences
EraGen Biosciences was acquired by Luminex Corporation in 2011.
ESBATech
ESBATech was acquired by Alcon in 2009.
FoldRx Pharmaceuticals
FoldRx Pharmaceuticals was acquired by Pfizer, Inc. in 2010.
Forendo Pharma
Forendo Pharma was acquired by Organon in 2021.
Genedata AG
NVF’s holdings in Genedata were acquired by Genedata in 2019.
GlycArt Biotechnology
GlycArt Biotechnology was acquired by Roche in 2005.
Heptares Therapeutics, Ltd
Heptares Therapeutics, Ltd was acquired by Sosei Group Corporation in 2015.
Inflazome
Inflazome was acquired by Roche in 2020.
Intellikine
Intellikine was acquired by Takeda Pharmaceutical Company Ltd. in 2012.
Kinetix Pharmaceuticals
Kinetix Pharmaceuticals was acquired by Amgen in 2004.
KuDOS Pharmaceuticals
KuDOS Pharmaceuticals was acquired by AstraZeneca in 2006.
Lemonaid Health
Lemonaid Health was acquired by 23andMe in 2021.
LigoCyte Pharmaceuticals
LigoCyte Pharmaceuticals was acquired by Takeda Pharmaceutical Company Ltd. In 2012.
Miikana Therapeutics
Miikana Therapeutics was acquired by EntreMed, Inc. (now CASI Pharmaceuticals, Inc.) in 2006.
Neurovance
Neurovance was acquired by Otsuka Pharmaceuticals in 2017.
Okairos
Okairos was acquired by GlaxoSmithKline in 2013.
Symetis
Symetis was acquired by Boston Scientific in 2017.
Syrxx
Syrxx was acquired by Takeda Pharmaceutical Company Ltd. In 2006.
Swiss Pharma Contract
Swiss Pharma Contract was acquired by Covance, Inc. in 2009.
Transform Pharmaceuticals
Transform Pharmaceuticals was acquired by Johnson & Johnson in 2005.
Viamet
Viamet’s clinical-stage antifungal portfolio acquired by NovaQuest Capital Management in 2018.
Visiogen
Visiogen was acquired by Abbott Laboratories in 2009.
Our investment team has proven experience
With successful backgrounds in medicine, science, legal, investment, and business development, our team has expertise in bringing exciting new drugs and treatments to patients all over the world.
Learn about our IPO successes
Since 1999, the Novartis Venture Fund team has guided a number of life science companies to IPO exits.